MarketPulse

pharmaceutical stocks

8 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Novartis Edges Out Merck as Superior Pharma Dividend Play

Novartis offers better dividend yields and diversification than Merck, with stronger long-term prospects despite both beating the S&P 500.
MRKNVSdividend stocksdividend yield
The Motley FoolThe Motley Fool··Eric Volkman

S&P 500 Dividend Yields Hit Historic Lows; Three Stocks Offer Superior Returns

S&P 500 dividend yields fall to 1.2% lows, but AbbVie, Procter & Gamble, and Coca-Cola offer yields of 3.20%, 2.91%, and 2.66% respectively.
JNJABBVKOPGS&P 500dividend growth
BenzingaBenzinga··Nabaparna Bhattacharya

Merck Shares Fall 3.12% Despite $53M Terns Pharma Acquisition Announcement

Merck stock fell 3.12% Tuesday despite announcing a $53-per-share acquisition of Terns Pharmaceuticals, pressured by broader market decline and healthcare sector weakness.
MRKTERNtechnical analysishealthcare sector
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Three Pharma Giants Poised for Growth: Lilly, Vertex, Pfizer Lead March 2026 Rally

Eli Lilly dominates weight management, Vertex controls cystic fibrosis, and Pfizer offers undervalued shares with 6.3% dividend yield.
PFELLYVRTXdividend yieldcystic fibrosis
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Pfizer vs. Moderna: Navigating Pharma's Post-Pandemic Pivot

Moderna's 69% YTD gain reflects mRNA vaccine upside, while Pfizer's 6.3% dividend offers stability as COVID revenues fade. Choice depends on risk appetite.
MRKPFEMRNAbiotechclinical trials
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Novartis Maintains Growth Trajectory Amid Patent Challenges, Dividend Consistency

Novartis maintains growth despite patent challenges, backed by a strong product portfolio of 15 billion-dollar brands and nearly 30 years of consecutive dividend increases.
NVSdividend growthlong-term investing
The Motley FoolThe Motley Fool··Emma Newbery

Novo Nordisk Shares Slide on CagriSema Trial Results

Novo Nordisk shares fell 16% after CagriSema obesity drug trial underperformed rival Eli Lilly's tirzepatide. Deutsche Bank downgraded the stock amid competitive concerns.
LLYNVSNVOweight losstirzepatide
The Motley FoolThe Motley Fool··Matthew Benjamin

Eli Lilly Positions Itself as Pharma Leader Through GLP-1 Dominance and Strategic M&A

Eli Lilly strengthens market position through GLP-1 dominance and strategic acquisitions like Orna Therapeutics, diversifying growth beyond patent cliff risks.
PFELLYacquisitionsgene therapy